CC PRE-TEST

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

Factors to convert immunoglobulin from mg/dL to g/L a. 0.01 b. 0.02586 c. 0.05551 d. 10

a. 0.01

Heparin is added _____ per mL of blood in each tube A. 0.2 mcg/mL B. 2.0 mcg/mL C. 0.2 mg/dL D. 2 mg/dL

C. 0.2 mg/dL

A blood sample is left on a phlebotomy tray for four hours before it is delivered to the laboratory. Which group of tests could still be performed? A)glucose, Na, K, Cl, PCO2 B)uric acid, BUN, creatinine C) total and direct bilirubin D)CK, ALT, ALP, ACP

B) uric acid, BUN, creatinine

What is used to zero the spectrophotometer before reading the test sample? Calibrator Sample blank Reagent blank Standard

Reagent blank

What is used to zero the spectrophotometer During reading the test sample? Calibrator Sample blank Reagent blank Standard

Sample blank

Type 3c Diabetes, EXCEPT: A. Autoimmune B. Cystic Fibrosis C. Hemochromatosis D. Pancreatitis

A. Autoimmune

creatine is synthesized in the liver from all of the following amino acids, EXCEPT: A. methionine B. cysteine C. glycine D. arginine

B. cysteine

It transport protein for thyroxine and triiodothyronine; it also binds with retinol-binding protein to form a complex that transports retinol (Vitamin A) A. Albumin B. Haptoglobin C. Orosomucoid D. Prealbumin

D. Prealbumin

A low ____ level is a sensitive marker of poor nutritional status. A. albumin B. haptoglobin C. prealbumin D. transferrin

C. prealbumin

Which of the following results would be most adversely affected by a non-fasting sample? A. HDL B. Triglycerides C. Cholesterol D. LDL

B. Triglycerides

Which of the following lipid tests is least affected by the fasting status of the patient? A. Cholesterol B. Triglycerides C. Fatty acid D. Lipoprotein

A. Cholesterol

Major roles of is to maintain the equilibrium of cholesterol in peripheral cells by the REVERSE CHOLESTEROL TRANSPORT pathway: A. Chylomicrons B. LDL C. VLDL D. HDL

D. HDL

Rare autosomal recessive disorder characterized by complete absence of HDL: a. Tangier disease b. Anderson disease c. Bassen-Kornzweig syndrome d. Sitosterolemia

a. Tangier disease

If left unprotected from light, bilirubin values may reduce by ____ per hour a. 10 to 30% b. 30 to 50% c. 50 to 70% d. 70 to 90%

b. 30 to 50%

The “gold standard” in the diagnosis of acute coronary syndrome (ACS): a. Fibronectin b. Cystatin C c. Troponin d. B-Trace Protein

c. Troponin

If elevated, which laboratory test would support a diagnosis of CONGESTIVE HEART FAILURE? a. Homocysteine b. Troponin c. Albumin cobalt binding d. B-type natriuretic peptide

d. B-type natriuretic peptide

ALP isoenzyme that will resist heat denaturation at 65°C for 30 minutes: a. Bone ALP b. Intestinal ALP c. Liver ALP d. Placental ALP

d. Placental ALP

Which of the following buffers is used in the IFCC recommended method for ALP? a. Glycine b. Phosphate c. 2-Amino-2-methyl-1- propanol d. Citrate

C. 2-Amino-2-methyl-1- propanol

Assay methods for AST are generally based on the principle of the Karmen method, which incorporates a coupled enzymatic reaction using: a. Glutamic oxaloacetic transaminase b. Glutamic pyruvic transaminase c. Lactate dehydrogenase d. Malate dehydrogenase

d. Malate dehydrogenase

A physician orders several laboratory tests on a 55-year-old male patient who Is complaining of pain, stiffness, fatigue and headaches. Based on the following serum test results, what is the most likely diagnosis? = ALP: significantly increased * GGT: normal a. Biliary obstruction b. Cirrhosis ¢. Osteitis deformans (Paget disease) d. Hepatitis

¢. Osteitis deformans (Paget disease)

A 42-year-old male presents with anorexia, nausea, fever, and icterus of the skin and mucous membranes. He noticed that his urine had appeared dark for the past several days. The physician orders a series of biochemical tests. Based on the following test results, what Is the most likely diagnosis? = ALP: slightly elevated * ALT: markedly elevated = AST: markedly elevated = GGT: slightly elevated = Serum total bilirubin: moderately elevated » Urine bilirubin: positive » Fecal urobilinogen: decreased a. Acute hepatitis b. Alcoholic cirrhosis ¢. Metastatic carcinoma of the pancreas d. Obstructive jaundice

a. Acute hepatitis

Given the following results: * ALP: slight increased * AST: slight increased = ALT: slight increased * GGT: slight increased This is most consistent with: a. Acute hepatitis b. Chronic hepatitis ¢. Obstructive jaundice d. Liver hemangioma

a. Acute hepatitis

Which of the following is both hormone and enzyme? a. ADH b. Angiotensin c. Acetylcholinesterase d. Renin

d. Renin

LOW LEVELS of maternal AFP indicate an increased risk for: a. Anencephaly b. Down syndrome c. Presence of twins d. Spina bifida

b. Down syndrome

Decreased T3 and T4, increased TSH: a. Primary hypothyroidism b. Secondary hypothyroidism c. Primary hyperthyroidism d. Secondary hyperthyroidism

a. Primary hypothyroidism

Hirsutism, which can be quantified using a measurement technique known as the: a. Ferriman-Gallwey scale b. Liley graph c. T-score d. Z-score

a. Ferriman-Gallwey scale

Which of the following is the most potent androgen? a. Androstenedione b. Dehydroepiandrosterone c. Androsterone d. Testosterone

d. Testosterone

Plumbism, a deleterious effect of gradual accumulation of ____ in body tissues, as a result of repeated exposure a. arsenic b. cyanide c. lead d. mercury

c. lead

The half-life of the circulating cocaine is: a. 0.5 t0 1 hour b 1 to 2 hours C 2 to 3hours d.3 to 4 hours

a. 0.5 t0 1 hour

Half-life of COCAINE:

0.5 0 1 hour

Half-life of BENZOYLECGONINE:

4 TO 7 HRS

Half-life of ECSTASY:

8 TO 9 HRS

Half-life of THC:

1 day after asingle use and 3to 5 days in chronic, heavy consumers

How should a laboratory verify the reference range it uses for a particular test? A. Call another laboratory B. Use the numbers from a textbook C. Test samples from healthy people D. Look on a medical internet site

C. Test samples from healthy people

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前